GSK Licenses Trispecific T-Cell Engager from Chimagen for Multiple Myeloma in Deal Worth Up to $750M
- GSK has agreed to license a preclinical trispecific T-cell engager (TCE) from China-based Chimagen Biosciences for the treatment of multiple myeloma.
- The agreement includes an upfront payment plus development and commercial milestones, with total potential deal value of up to $750 million.
- Unlike currently approved bispecific TCEs in myeloma, the candidate binds T cells while simultaneously engaging two validated tumor-associated antigens, a design intended to improve efficacy and tolerability.
- The program remains preclinical; GSK expects the asset to enter Phase I trials in 2027.
- This is GSK's second licensing deal with Chimagen, following a 2024 agreement worth up to $850 million for a separate TCE targeting B-cell-mediated autoimmune disease.
Preclinical asset, real money: up to $750M for a molecule years from human data is a differentiation bet, not a de-risking buy — GSK is wagering the third binding arm clears a bar that Tecvayli, Talvey, and Elrexfio already set. Trispecific design is the pitch, but myeloma TCEs are now a crowded field; incremental antigen coverage has to translate into durability or safety gains, not just a cleaner mechanism story. Second Chimagen deal in under two years (after the $850M autoimmune TCE in 2024) turns a one-off license into a platform relationship — GSK is treating this China-based biotech's engineering as a recurring pipeline source, echoing the broader Western-pharma pivot to China for early oncology assets. Phase I isn't until 2027, so this is a multi-year credibility test for GSK's TCE bet across both oncology and autoimmune.
GSK strikes deal for Chimagen's T cell engager for blood cancer ↗